Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

Inclusion Criteria: * Histologically proven first diagnosis of cHL * Stage I-II without risk factors * Large mediastinal mass * Extranodal involvement * Elevated erythrocyte sedimentation rate (ESR) * Involvement of ≥ 3 nodal areas Exclusion Criteria: * Central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma, * Prior cHL-directed treatment * Prior chemotherapy, RT or allogeneic stem cell/solid organ transplant * Prior or concurrent disease precluding protocol treatment (for details see section 4.2) * Pregnancy or breastfeeding * Non-compliance